biote Corp. BTMD
1.09 USD +0.01 (+0.93%)
At closeNov 11, 2026, 4:00 PM EST
1.09 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
1.08 Day range 1.12
0.99 52-week range 2.90
- YTD
- -58.08%
- 1 year
- -58.24%
News
seekingalpha.com biote Corp. (BTMD) Q3 2026 Earnings Call Transcript biote Corp. ( BTMD ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Robert Peterson - Interim CEO, CFO & Chief Business Officer Conference Call Participants Szymon Serowiecki…
zacks.com biote Corp. (BTMD) Tops Q3 Earnings Estimates biote Corp. (BTMD) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to earnings of $0.22 per share a year ago.
benzinga.com Biote Q3 2026 Earnings Call Transcript Biote (NASDAQ:BTMD) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
businesswire.com Biote Reports Third Quarter 2026 Financial Results IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today…
defenseworld.net Head-To-Head Survey: The Pennant Group (NASDAQ:PNTG) vs. biote (NASDAQ:BTMD) biote (NASDAQ: BTMD - Get Free Report) and The Pennant Group (NASDAQ: PNTG - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two…
businesswire.com Biote Schedules Third Quarter 2026 Financial Results Release and Conference Call IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our…
defenseworld.net biote (NASDAQ:BTMD) and Elevance Health (NYSE:ELV) Head to Head Review Elevance Health (NYSE: ELV - Get Free Report) and biote (NASDAQ: BTMD - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock…
benzinga.com B. Riley Securities Maintains Neutral on Biote, Lowers Price Target to $1.5 B. Riley Securities analyst Jeff Van Sinderen maintains Biote (NASDAQ:BTMD) with a Neutral and lowers the price target from $2 to $1.5.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
seekingalpha.com biote Corp. (BTMD) Q2 2026 Earnings Call Transcript biote Corp. (BTMD) Q2 2026 Earnings Call Transcript
zacks.com biote Corp. (BTMD) Reports Break-Even Earnings for Q2 biote Corp. (BTMD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.1 per share a year ago.
marketbeat.com biote Q2 Earnings Call Highlights biote NASDAQ: BTMD reported lower second-quarter revenue and a net loss as a voluntary recall of certain hormone pellets supplied by Asteria Health disrupted procedure volumes, while management said…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…
benzinga.com Biote Q2 EPS $(0.23) Misses $0.04 Estimate, Sales $44.232M Miss $46.148M Estimate Biote (NASDAQ:BTMD) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $0.04 by 675 percent. This is a 330 percent decrease over earnings of $0.10 per share…
businesswire.com Biote Reports Second Quarter 2026 Financial Results IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today…
businesswire.com Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our…
businesswire.com Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr.…
gurufocus.com Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO [url="]Biote[/url] (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' pa
benzinga.com Biote Reaffirms FY26 Guidance For Revenue Above $190M And Adjusted EBITDA Above $38M Biote reaffirmed its full year 2026 guidance for revenue above $190 million, Adjusted EBITDA above $38 million, and a return to procedure revenue growth in the second half of this year.
benzinga.com Biote Appoints CFO And Chief Business Officer Bob Peterson As Interim CEO And Director, Effective June 8; Bret Christensen Steps Down As CEO Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief…
businesswire.com Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today…
seekingalpha.com biote Corp. (BTMD) Q1 2026 Earnings Call Transcript biote Corp. (BTMD) Q1 2026 Earnings Call Transcript
zacks.com biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago.- benzinga.com Biote Q1 2026 Earnings Call: Complete Transcript
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Biote Q1 EPS $0.06 Beats $0.03 Estimate, Sales $44.935M Miss $46.023M Estimate Biote (NASDAQ:BTMD) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 83.78 percent decrease over earnings of $0.37 per share…
businesswire.com Biote Reports First Quarter 2026 Financial Results IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today…
businesswire.com Biote Schedules First Quarter 2026 Financial Results Release and Conference Call IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our…- benzinga.com Truist Securities Maintains Buy on Biote, Lowers Price Target to $4 Truist Securities analyst Gregory Fraser maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $5 to $4.
- benzinga.com B. Riley Securities Maintains Neutral on Biote, Lowers Price Target to $2 B. Riley Securities analyst Jeff Van Sinderen maintains Biote (NASDAQ:BTMD) with a Neutral and lowers the price target from $3 to $2.
seekingalpha.com biote Corp. (BTMD) Q4 2025 Earnings Call Transcript biote Corp. (BTMD) Q4 2025 Earnings Call Transcript
zacks.com biote Corp. (BTMD) Q4 Earnings and Revenues Top Estimates biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.1 per share a year ago.
benzinga.com Biote Q4 EPS $0.06 Beats $0.05 Estimate, Sales $46.408M Beat $46.190M Estimate Biote (NASDAQ:BTMD) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 40 percent decrease over earnings of $0.10 per share…- benzinga.com Earnings Scheduled For March 11, 2026
benzinga.com Earnings Outlook For Biote - benzinga.com Biote Expects $1.3M Charge For Q4 Due To Recall Of Specific Lots Of Hormone Pellets; Additional Recall Costs In 2026 Estimated At $1.0M On January 26, 2026, F.H. Investments, Inc. ("Asteria Health"), a 503B manufacturer of compounded bioidentical hormones and wholly-owned subsidiary of biote Corp. (the "Company"), out of an abundance…
- benzinga.com Biote Affirms FY2025 Sales Guidance of $190.000M vs $192.670M Est Biote (NASDAQ:BTMD) affirms FY2025 sales outlook from $190.000 million to $190.000 million vs $192.670 million estimate.
- benzinga.com Biote Q3 EPS $0.22 Beats $0.07 Estimate, Sales $47.956M Beat $47.757M Estimate Biote (NASDAQ:BTMD) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.07 by 214.29 percent. This is a 33.33 percent decrease over earnings of $0.33 per…
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com B. Riley Securities Downgrades Biote to Neutral, Lowers Price Target to $4 B. Riley Securities analyst Jeff Van Sinderen downgrades Biote (NASDAQ:BTMD) from Buy to Neutral and lowers the price target from $8 to $4.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com Biote Lowers FY2025 Sales Guidance from $202.000M-$208.000M to $190.000M vs $204.667M Est Biote (NASDAQ:BTMD) lowers FY2025 sales outlook from $202.000 million-$208.000 million to $190.000 million vs $204.667 million estimate.
- benzinga.com Biote Q2 EPS $0.10 Beats $0.06 Estimate, Sales $48.90M Miss $49.52M Estimate Biote (NASDAQ:BTMD) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.06 by 58.73 percent. This is a 152.63 percent increase over losses of $(0.19) per…
- benzinga.com Earnings Scheduled For August 6, 2025
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Biote Affirms FY2025 Sales Guidance of $202.00M-$208.00M vs $205.31M Est Biote (NASDAQ:BTMD) affirms FY2025 sales outlook from $202.00 million-$208.00 million to $202.00 million-$208.00 million vs $205.31 million estimate.
benzinga.com Biote Q1 EPS $0.37 Beats $0.07 Estimate, Sales $48.99M Beat $46.99M Estimate Biote (NASDAQ:BTMD) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.07 by 428.57 percent. This is a 716.67 percent increase over losses of $(0.06) per…- benzinga.com Earnings Scheduled For May 7, 2025